Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br YKK was a consultant

    2019-11-05


    YKK was a consultant for Blueprint, Bristol-Meyers Squibb, Daehwa, LSK Biopharma, Merck Serono, Novartis, Ono and Roche.
    HCC has received research grants from Eli Lilly, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Ono and Taiho, served on speakers bureaus for Eli Lilly, Foundation Medicine and Merck Serono and has been a consultant for Bristol-Meyers Squibb, Celltrion, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Quintiles and Taiho.
    ZAW has been a consultant for Array, FivePrime, Genentech, Merck Serono, Merck Sharp & Dohme and Novartis.
    WC has nothing to disclose but was a stockholder and employee of Genentech/Roche.
    SG, NX, DM and RM are employees of Genentech, Inc.
    IC has served as an advisor for AstraZeneca, Bayer, Bristol-Meyers Squibb, Eli Lilly, FivePrime, Merck Serono, Merck Sharp & Dohme and Roche, received research funding from Eli Lilly, Janssen-Cilag, Merck Serono and Sanofi Oncology and honoraria from Eli Lilly.
    MN and JAA have nothing to disclose.
    Acknowledgments
    We thank the patients and their o-Phenanthroline who partici-pated in the study and all the investigators and their staff. Medical writing assistance was provided by Health Interactions, Inc. and funded by F. Hoffmann-La Roche Ltd.
    Appendix A. Supplementary data
    References
    [1] Brown JS, Banerji U. Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther 2017 Apr;172:101e15.
    [4] Cancer Genome Atlas Research Network. Comprehensive mo-lecular characterization of gastric adenocarcinoma. Nature 2014 Sep 11;513(7517):202e9.
    [6] Kim SB, Dent R, Im SA, Espie M, Blau S, Tan AR, et al. Ipa-tasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2017 Oct;18(10):1360e72.
    [10] Saura C, Roda D, Rosello S, Oliveira M, Macarulla T, Perez-Fidalgo JA, et al. A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov 2017 Jan;7(1):102e13.
    [11] Jin P, Wong CC, Mei S, He X, Qian Y, Sun L. MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemo-sensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation. OncoTargets Ther 2016 Jul 19;9:4387e96.
    [12] Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, et al. CALGB 80403 (alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol 2016 Aug 10;34(23):2736e42.
    [13] McCarty Jr KS, Miller LS, Cox EB, Konrath J, McCarty KSS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985 Aug;109(8):716e21.
    [15] Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011 Oct 20; 29(30):3968e76.
    [16] Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013 May;14(6):481e9.
    [17] Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013 May;14(6):490e9.